Literature DB >> 19763667

Cyclosporine A-induced neck fibrosis in a patient with adult-onset Still's disease.

Senol Kobak1, Recep Savas, Fahrettin Oksel, Eker Doganavsargil.   

Abstract

Cyclosporine A (CsA) is an immunosuppressive agent used for the prevention of graft rejection during organ and bone marrow transplantation. CsA is also used for the treatment of various inflammatory rheumatic diseases. Although different side effect profiles have been reported, nephrotoxicity, renal vascular damage, hypertension, and gingival hypertrophy are among the most commonly encountered side effects. The development of massive fibrosis in the neck associated with CsA in a 30-year-old male patient with Still's disease is presented herein. Significant regression was observed after the discontinuation of CsA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763667     DOI: 10.1007/s10067-009-1275-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

Authors:  P Tugwell; C Bombardier; M Gent; K J Bennett; W G Bensen; S Carette; A Chalmers; J M Esdaile; A V Klinkhoff; G R Kraag
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 2.  Medically induced gingival hyperplasia.

Authors:  S J Meraw; P J Sheridan
Journal:  Mayo Clin Proc       Date:  1998-12       Impact factor: 7.616

3.  Pre-transplant gingival hyperplasia predicts severe cyclosporin-induced gingival overgrowth in renal transplant patients.

Authors:  E Varga; M A Lennon; L H Mair
Journal:  J Clin Periodontol       Date:  1998-03       Impact factor: 8.728

4.  In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine.

Authors:  G T Shin; A Khanna; R Ding; V K Sharma; M Lagman; B Li; M Suthanthiran
Journal:  Transplantation       Date:  1998-02-15       Impact factor: 4.939

5.  The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry.

Authors:  C A Marra; J M Esdaile; D Guh; J H Fisher; A Chalmers; A H Anis
Journal:  Arthritis Rheum       Date:  2001-06

6.  Immunohistochemical study of 30 cases of cyclosporin A-induced gingival overgrowth.

Authors:  F O'Valle; F L Mesa; M Gómez-Morales; D Aguilar; M D Caracuel; M T Medina-Cano; M Andújar; J López-Hidalgo; R García del Moral
Journal:  J Periodontol       Date:  1994-07       Impact factor: 6.993

7.  Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.

Authors:  C Salvarani; P Macchioni; L Boiardi; F Rossi; M Casadei Maldini; R Mancini; E Beltrandi; L Lodi; G Bisighini; I Portioli
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 8.  The pathogenesis of drug-induced gingival overgrowth.

Authors:  R A Seymour; J M Thomason; J S Ellis
Journal:  J Clin Periodontol       Date:  1996-03       Impact factor: 8.728

Review 9.  Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life.

Authors:  C Bombardier; R Buchbinder; P Tugwell
Journal:  Scand J Rheumatol Suppl       Date:  1992

10.  Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia.

Authors:  T D Daley; G P Wysocki; C Day
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1986-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.